Board of Directors
Chairman and Managing Partner, Visionary Venture Fund
Jeffry Weinhuff is a managing partner of Visionary Venture Fund, a late-stage venture capital fund exclusively focused on investing in the most promising ophthalmology companies. Mr. Weinhuff has been active in the private equity realm for over 30 years. At Jefferies & Co., a premier mid-market investment bank, he founded the investment banking and capital markets groups, served as the head of investment banking and the commitment committee, and was a member of the board of directors. Prior to Jefferies, Mr. Weinhuff was a partner at Drexel Burnham Lambert, where he founded and co-headed the buyer advisory group and served on the underwriting committee.
Mr. Weinhuff holds an MBA from the Marshall School of Business at the University of Southern California and a B.S. in economics from the University of California, Santa Barbara.
Senior Global Pharmaceutical Executive
Luzi von Bidder is an experienced industry executive who served for over 17 years as chairman and chief executive officer of Novartis Ophthalmics AG and as a member of the Novartis pharma executive committee. Currently he is on the board of directors of several private healthcare companies. Most recently, Mr. von Bidder was chairman of the Swiss listed company Acino Holding AG. Mr. von Bidder is the founder of four healthcare startups and has extensive experience in the M&A field.
Mr. von Bidder holds an MBA and a B.A. in economics from University of St. Gallen.
Partner, Sequoia Capital
Yoav Shaked is a business leader with over 15 years of executive and entrepreneurial experience in the healthcare and medical device industry. Prior to Sequoia, he co-founded MedPoint Technologies Ltd., and founded YMed, which was later acquired by C.R. Bard.
Mr. Shaked currently serves as a board member at the following companies: Endospan, Polytech GmbH, Vibrant Gastro, and Dario Health.
Mr. Shaked holds a B.A. in biology from the Hebrew University of Jerusalem.
SBI (Japan) Innovation Ventures
Mr. Tanaka launched SBI JI Innovation Fund L.P. in 2017 to focus on investments in life science as well as information and communication technologies in Israel. Previously, he played a key role in closing a strategic partnership with Vertex Venture Capital Israel and executing two new investments in Israeli cyber security startups. Prior to that, Mr. Tanaka held various leadership positions at the SBI Group, including manager of the CEO’s office and other senior positions in the overseas business development division at SBI Holdings, Inc., as well as engaging in the operation of a private equity fund in Southeast Asia at SBI Ven Capital Pte. Ltd.
Mr. Tanaka holds a Bachelor of Commerce in marketing and accounting from Waseda University.
Chief Executive Officer
Elad Kedar has nearly 20 years of executive experience in the pharmaceutical industry, developing and growing healthcare organizations. His experience includes holding a variety of senior positions across different geographic locations and business environments, such as CFO of Eli Lilly South-East Europe and founder of PharmaSwiss Israel. Mr. Kedar brings his leadership and expertise to all stages of the pharmaceutical life cycle, from clinical development to commercialization.
Mr. Kedar holds an MBA from INSEAD and a B.A. in accounting and law from Tel Aviv University.